EP2007755B1 — Fused ring thrombin receptor antagonists
Assigned to Merck Sharp and Dohme LLC · Expires 2012-06-27 · 14y expired
What this patent protects
Fused-ring, heterocyclic-substituted tricyclics of the Formula (I) or a pharmaceutically acceptable salt or solvate of said compound, isomer or racemic mixture wherein Formula (II) represents an optional double bond, and wherein An, En, Mn, Gn, Jn, R3, n7, R8, R9, R10, R11, R32, …
USPTO Abstract
Fused-ring, heterocyclic-substituted tricyclics of the Formula (I) or a pharmaceutically acceptable salt or solvate of said compound, isomer or racemic mixture wherein Formula (II) represents an optional double bond, and wherein An, En, Mn, Gn, Jn, R3, n7, R8, R9, R10, R11, R32, R33, X, Y, B and Het are herein defined and the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.